STOCK TITAN

Absci Corp - ABSI STOCK NEWS

Welcome to our dedicated news page for Absci (Ticker: ABSI), a resource for investors and traders seeking the latest updates and insights on Absci.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Absci's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Absci's position in the market.

Rhea-AI Summary
Absci (ABSI) will report business updates and first quarter 2024 financial and operating results on May 14, 2024. The company will host a webcast to discuss its developments, results, and outlook.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.92%
Tags
conferences earnings
-
Rhea-AI Summary
Absci (ABSI) to participate in the 23rd Annual Needham Virtual Healthcare Conference. Management will present on April 8th, 2024, at 3:00 p.m. ET. Access the webcast on investors.absci.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.23%
Tags
conferences
-
Rhea-AI Summary
Absci (Nasdaq: ABSI) reported financial and operating results for Q4 and year ended December 31, 2023. The company initiated IND-enabling studies for ABS-101, a potential best-in-class anti-TL1A antibody, and entered a collaboration with AstraZeneca for up to $247M in deal value. Absci also raised approximately $86M through a common stock offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.73%
Tags
Rhea-AI Summary
Biopharmaceutical companies are seeing significant developments in their portfolios. AceLink Therapeutics published positive Phase 1 clinical trial data for AL01211, Basking Biosciences secured $55 million for stroke therapy development, Technoderma Medicines received multi-million dollar financing for hair loss and dermatitis projects, Full-Life Technologies raised $63.3 million for radiopharmaceutical pipeline, and Absci partnered with AstraZeneca for AI-driven oncology candidate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.9%
Tags
none
-
Rhea-AI Summary
Absci Corporation (ABSI) successfully closes underwritten public offering, raising approximately $86.4 million for drug development and platform investment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.13%
Tags
-
Rhea-AI Summary
Absci Corporation (ABSI) announced a public offering of 16.7 million shares of common stock at $4.50 per share, expecting to raise approximately $75.2 million. The proceeds will fund internal asset programs, AI technology, and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.67%
Tags
Rhea-AI Summary
Absci Corporation (Nasdaq: ABSI) has announced a public offering of $75.0 million of its common stock, with an option for underwriters to purchase an additional $11.25 million. The proceeds will fund internal asset programs, investment in its Integrated Drug Creation™ platform, and general corporate purposes. Morgan Stanley and TD Cowen are the joint book-running managers for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.67%
Tags
-
Rhea-AI Summary
Absci Corporation announces the initiation of IND-enabling studies for ABS-101, a promising anti-TL1A antibody, designed using its generative AI model. The company aims to submit an IND in Q1 2025 and commence Phase 1 trials soon after, showcasing the potential for faster drug discovery using AI technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.18%
Tags
AI
-
Rhea-AI Summary
Absci Corporation (ABSI) announces its participation in several upcoming investor conferences, including TD Cowen 44th Annual Health Care Conference and KeyBanc Capital Markets Emerging Technology Summit. The company will engage in fireside chats to discuss its AI-based drug creation technology. Interested parties can access live and archived webcasts of these events on the company's investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.76%
Tags
conferences
Rhea-AI Summary
Absci (Nasdaq: ABSI) appoints Professor Sir Menelas 'Mene' Pangalos, a distinguished biopharmaceutical executive, to its Board of Directors and as co-chair of Absci’s Scientific Advisory Board. Sir Pangalos, with over 25 years of experience in drug discovery and development, joins Absci as the company scales its AI-enabled portfolio of partnered and wholly-owned assets. His appointment follows the recent addition of former Phillips CEO Frans van Houten to the Board. Absci’s recent collaborations with AstraZeneca and Almirall underscore its commitment to leveraging AI to bring impactful drugs to patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.06%
Tags
management
Absci Corp

Nasdaq:ABSI

ABSI Rankings

ABSI Stock Data

606.78M
80.69M
22.65%
37.86%
9.3%
Testing Laboratories
Professional, Scientific, and Technical Services
Link
United States
Vancouver